published meta-analysis   sensitivity analysis   studies

interferon in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsSOLIDARITY (interferon), 2020 1.16 [0.96; 1.40] 1.16[0.96; 1.40]SOLIDARITY (interferon), 202010%4,100moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsYekaninejad, 2020 3.41 [1.33; 8.73] 3.41[1.33; 8.73]Yekaninejad, 202010%66moderatenot evaluable death or ventilationdetailed resultsSOLIDARITY (interferon), 2020 1.05 [0.90; 1.23] 1.05[0.90; 1.23]SOLIDARITY (interferon), 202010%4,100moderatenot evaluable hospital dischargedetailed resultsYekaninejad, 2020 3.44 [0.64; 18.49] 3.44[0.64; 18.49]Yekaninejad, 202010%66moderatenot evaluable ventilationdetailed resultsYekaninejad, 2020 0.29 [0.05; 1.56] 0.29[0.05; 1.56]Yekaninejad, 202010%66moderatenot evaluable ICU admissiondetailed resultsYekaninejad, 2020 0.37 [0.14; 1.00] 0.37[0.14; 1.00]Yekaninejad, 202010%66moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2020-11-28 06:41 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 517,740,687 - roots T: 290